Actym Therapeutics adds $25.5 million to close its Series A with $59.5 million total New investor GKCC LLC joins syndicate Capital will propel lead program ACTM-838 into first-in-human oncology trial and further advance proprietary STACT platform BERKELEY, CA — October 18, 2023 Actym Therapeutics, pioneering a new drug modality to treat solid tumors, announced today […]
DZD Presents Direct-From-Blood, Rapid Antimicrobial Susceptibility Testing at the 2024 ASM Microbe conference
DZD Presents Direct-From-Blood, Rapid Antimicrobial Susceptibility Testing at the 2024 ASM Microbe conference
Utilizing our DeliverEX™ platform, we are engineering exosomes to deliver protein and nucleic acid-based therapeutics to treat life-threatening rare diseases. At Evox Therapeutics we are harnessing the natural targeting and delivery capabilities of exosomes to engineer an entirely novel class of biotherapeutics.
Utilizing our DeliverEX™ platform, we are engineering exosomes to deliver protein and nucleic acid-based therapeutics to treat life-threatening rare diseases. At Evox Therapeutics we are harnessing the natural targeting and delivery capabilities of exosomes to engineer an entirely novel class of biotherapeutics.